cost plus drugs glp-1 Mark Cuban has compelling words about Ozempic and These statements have not been evaluated by the Food and Drug Administration How Employers Can Manage GLP-1

Others have dropped it because the short-term expense is enormous

Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus

The most common reasons include: Gastrointestinal side effects such as nausea, vomiting and diarrhea which are the single most frequently documented reason for stopping in large health system datasets High out of pocket cost and lack of insurance coverage particularly in individuals without diabetes Medication unavailability or pharmacy supply shortages which peaked in 2023early 2024 Perceived completion of therapy once target weight is reached or weight loss plateaus Concerns about long term safety or treatment burden of injections Many cohorts show substantial discontinuation by 3 months, with further losses by 6-9 months

(January 2026)

Confirm your pricing trajectory before committing